$TOI
Oncology Institute, Inc. Stock $toi

$toi Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000162828022013677 Filed on May 10, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$60.92M	$55.16M	$52.30M
YoY Change	22.22%	13.55%
Cost Of Revenue	$49.78M	$42.84M	$43.97M
YoY Change	27.79%	11.62%	15.35%
Gross Profit	$11.14M	$12.32M	$8.333M
YoY Change	2.31%	20.78%	-23.13%
Gross Profit Margin	18.29%	22.34%	15.93%
Selling, General & Admin	$28.35M	$29.81M	$48.25M
YoY Change	152.83%	166.65%	23659.06%
% of Gross Profit	254.42%	241.89%	578.95%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.098M	$987.0K	$919.4K
YoY Change	38.22%	27.03%	16.38%
% of Gross Profit	9.85%	8.01%	11.03%
Operating Expenses	$29.45M	$29.81M	$49.16M
YoY Change	145.24%	166.65%	24111.84%
Operating Profit	-$18.30M	-$18.47M	-$40.83M
YoY Change	594.44%	953.68%	-483.86%
Interest Expense	-$61.00K	$74.00K	-$60.11K
YoY Change	-24.61%	-26.73%	-99.2%
% of Operating Profit
Other Income/Expense, Net	$12.88M	$37.94M	$28.50M
YoY Change	-333778.76%	3790.97%	-9144.52%
Pretax Income	-$5.485M	$19.47M	-$12.62M
YoY Change	-10.39%	-2602.06%	56.96%
Income Tax	-$32.00K	$180.0K	-$2.467M
% Of Pretax Income		0.92%
Net Earnings	-$5.453M	$19.29M	-$10.16M
YoY Change	-10.91%	-2036.35%	26.3%
Net Earnings / Revenue	-8.95%	34.96%	-19.42%
Basic Earnings Per Share	-$0.06	$0.22
Diluted Earnings Per Share	-$74.70K	$0.21	-$138.7K
COMMON SHARES
Basic Shares Outstanding	73.28M shares	73.25M shares
Diluted Shares Outstanding	73.00M shares	76.25M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$64.21M	$94.66M	$115.2M
YoY Change	10256.13%	16410.39%	12460.01%
Cash & Equivalents	$64.21M	$95.53M	$115.2M
Short-Term Investments
Other Short-Term Assets	$10.05M	$11.62M	$11.20M
YoY Change	7629.23%	7035.66%	7245.71%
Inventory	$8.580M	$7.770M	$6.438M
Prepaid Expenses		$10.74M	$11.20M
Receivables	$28.95M	$24.51M	$20.01M
Other Receivables	$422.0K	$1.279M	$1.237M
Total Short-Term Assets	$112.2M	$139.8M	$154.1M
YoY Change	14917.11%	18895.87%	418.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$23.27M	$4.909M	$4.192M
YoY Change			99.24%
Goodwill		$26.63M	$26.63M
YoY Change			87.15%
Intangibles		$17.57M	$18.25M
YoY Change			-6.51%
Long-Term Investments
YoY Change
Other Assets	$407.0K	$332.0K	$320.0K
YoY Change			162.3%
Total Long-Term Assets	$77.54M	$66.67M	$49.38M
YoY Change	-66.29%	-71.05%	37.29%
TOTAL ASSETS
Total Short-Term Assets	$112.2M	$139.8M	$154.1M
Total Long-Term Assets	$77.54M	$66.67M	$49.38M
Total Assets	$189.7M	$206.5M	$203.4M
YoY Change	-17.77%	-10.61%	209.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.90M	$12.60M	$15.56M
YoY Change	1345.42%	50875.31%	23.06%
Accrued Expenses	$17.33M	$14.52M	$13.92M
YoY Change	1040.0%	9783.57%	47.31%
Deferred Revenue			$262.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$183.0K
YoY Change			-96.59%
Total Short-Term Liabilities	$36.13M	$31.52M	$29.80M
YoY Change	1334.57%	18272.09%	4.16%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$29.13M	$3.801M	$6.900M
YoY Change	28.26%	-80.22%	755.02%
Total Long-Term Liabilities	$29.13M	$3.801M	$6.900M
YoY Change	28.26%	-80.22%	-6.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$36.13M	$31.52M	$29.80M
Total Long-Term Liabilities	$29.13M	$3.801M	$6.900M
Total Liabilities	$65.76M	$74.51M	$99.28M
YoY Change	160.69%	284.37%	164.13%
SHAREHOLDERS EQUITY
Retained Earnings		-$43.95M	-$63.23M
YoY Change			20.89%
Common Stock		$7.000K	$7.000K
YoY Change			16.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$124.0M	$132.0M	$104.2M
YoY Change
Total Liabilities & Shareholders Equity	$189.7M	$206.5M	$203.4M
YoY Change	-17.77%	-10.61%	209.7%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$5.453M	$19.29M	-$10.16M
YoY Change	-10.91%	-2036.35%	26.3%
Depreciation, Depletion And Amortization	$1.098M	$987.0K	$919.4K
YoY Change	38.22%	27.03%	16.38%
Cash From Operating Activities	-$10.38M	-$16.98M	-$23.34M
YoY Change	875.47%	-3759.7%	28500.67%
INVESTING ACTIVITIES
Capital Expenditures	-$1.342M	$1.002M	-$871.4K
YoY Change		61.87%	-348.96%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities	-$8.920M	$0.00	-$8.280M
YoY Change	-891.48%	-100.0%
Cash From Investing Activities	-$10.26M	-$1.002M	-$9.151M
YoY Change	-687.74%	-30.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	-10.69M	-$1.657M	136.1M
YoY Change		-107.4%
NET CHANGE
Cash From Operating Activities	-10.38M	-$16.98M	-23.34M
Cash From Investing Activities	-10.26M	-$1.002M	-9.151M
Cash From Financing Activities	-10.69M	-$1.657M	136.1M
Net Change In Cash	-31.33M	-$19.64M	103.6M
YoY Change	-4693.26%	-191.72%	-127127.26%
FREE CASH FLOW
Cash From Operating Activities	-$10.38M	-$16.98M	-$23.34M
Capital Expenditures	-$1.342M	$1.002M	-$871.4K
Free Cash Flow	-$9.037M	-$17.98M	-$22.46M
YoY Change		11501.94%	5104.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001799191
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-39248
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	The Oncology Institute, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-3562323
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	18000 Studebaker Rd, Suite 800
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cerritos
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90703
CY2022Q1	dei	City Area Code CityAreaCode	562
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	735-3226
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	73276230	shares
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	875000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	875000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95534000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115174000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24513000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20007000	USD
CY2022Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1279000	USD
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1237000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	7770000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	6438000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10744000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11200000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	139840000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	154056000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4909000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4192000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17233000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	17572000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18245000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	26626000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	26626000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	332000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	320000	USD
CY2022Q1	us-gaap	Assets Assets	206512000	USD
CY2021Q4	us-gaap	Assets Assets	203439000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4277000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2022Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	183000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	12596000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15559000	USD
CY2022Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	132000	USD
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	132000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14516000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13924000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	31521000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29798000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14409000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2022Q1	toi	Derivative Warrant Liabilities Noncurrent DerivativeWarrantLiabilitiesNoncurrent	3654000	USD
CY2021Q4	toi	Derivative Warrant Liabilities Noncurrent DerivativeWarrantLiabilitiesNoncurrent	2193000	USD
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	20578000	USD
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	60018000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3801000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6900000	USD
CY2022Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	551000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	371000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	74514000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	99280000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73276230	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73276230	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73249042	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73249042	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	163510	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	163510	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	131998000	USD
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	987000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	777000	USD
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	73632000	USD
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	163510	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	163510	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	175939000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	167386000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43948000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63234000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	104159000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	206512000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	203439000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55161000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48580000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29806000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11178000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8553000	USD
CY2021Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	50333000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18471000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1753000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	74000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	101000	USD
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1461000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	39440000	USD
CY2021Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	183000	USD
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-151000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1076000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	37937000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	975000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	19466000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-778000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	180000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	218000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	19286000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-996000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.22
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73252365	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62853419	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	76247966	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62853419	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	104159000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	19286000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	131998000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	28101000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-996000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	19999000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	42000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	47146000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	19286000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-996000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	987000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	777000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	18000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8553000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	42000	USD
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1461000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	39440000	USD
CY2021Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	180000	USD
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	221000	USD
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	183000	USD
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	154000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-14000	USD
CY2021Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4660000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	550000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1332000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-10000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	42000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	20000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-456000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-56000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	353000	USD
CY2022Q1	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	-942000	USD
CY2021Q1	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	0	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	11000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	37000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	526000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	358000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	102000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2963000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	474000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-909000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2022Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	362000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16981000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	464000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1002000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	619000	USD
CY2022Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2021Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	827000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1002000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1446000	USD
CY2021Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2500000	USD
CY2022Q1	toi	Payments For Financing Of Insurance Payments PaymentsForFinancingOfInsurancePayments	1235000	USD
CY2021Q1	toi	Payments For Financing Of Insurance Payments PaymentsForFinancingOfInsurancePayments	0	USD
CY2022Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	409000	USD
CY2021Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	USD
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2021Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	94000	USD
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	13000	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	10000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	20000000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1657000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22396000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-19640000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	21414000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115174000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5998000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95534000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27412000	USD
CY2022Q1	toi	Interest And Principal Forgiven From Paycheck Protection Program Loan Cares Act InterestAndPrincipalForgivenFromPaycheckProtectionProgramLoanCaresAct	183000	USD
CY2021Q1	toi	Interest And Principal Forgiven From Paycheck Protection Program Loan Cares Act InterestAndPrincipalForgivenFromPaycheckProtectionProgramLoanCaresAct	0	USD
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	74000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2022Q1	toi	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	3	subsidiary
CY2022Q1	toi	Number Of Oncologists And Mid Level Professionals Within Three States Minimum NumberOfOncologistsAndMidLevelProfessionalsWithinThreeStatesMinimum	84	oncologist
CY2022Q1	toi	Number Of Clinic Locations NumberOfClinicLocations	53	clinic
CY2022Q1	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	4	state
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates under different assumptions or conditions. Significant items subject to such estimates and assumptions include judgements related to revenue recognition, estimated accounts receivable, useful lives and recoverability of long-lived and intangible assets, recoverability of goodwill, fair values of acquired assets and assumed liabilities in business combinations, fair value of intangible assets and goodwill, fair value of share-based compensation, fair value of liability classified instruments, and judgements related to deferred income taxes.</span></div>
CY2021	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	5142000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24513000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20007000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	177000	USD
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	23000	USD
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55161000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48580000	USD
CY2022Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	220000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	220000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	7770000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	6438000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	95534000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	115174000	USD
CY2022Q1	us-gaap	Accounts Receivable Fair Value Disclosure AccountsReceivableFairValueDisclosure	24513000	USD
CY2021Q4	us-gaap	Accounts Receivable Fair Value Disclosure AccountsReceivableFairValueDisclosure	20007000	USD
CY2022Q1	toi	Other Receivables Fair Value Disclosure OtherReceivablesFairValueDisclosure	1279000	USD
CY2021Q4	toi	Other Receivables Fair Value Disclosure OtherReceivablesFairValueDisclosure	1237000	USD
CY2022Q1	us-gaap	Accounts Payable Fair Value Disclosure AccountsPayableFairValueDisclosure	12596000	USD
CY2021Q4	us-gaap	Accounts Payable Fair Value Disclosure AccountsPayableFairValueDisclosure	15559000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2294000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1984000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4909000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4192000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	314000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	165000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4186000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3325000	USD
CY2022Q1	toi	Contract Liabilities And Refund Liabilities ContractLiabilitiesAndRefundLiabilities	220000	USD
CY2021Q4	toi	Contract Liabilities And Refund Liabilities ContractLiabilitiesAndRefundLiabilities	592000	USD
CY2022Q1	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	5057000	USD
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	5009000	USD
CY2022Q1	toi	Business Combination Consideration Transferred Other Current BusinessCombinationConsiderationTransferredOtherCurrent	2050000	USD
CY2021Q4	toi	Business Combination Consideration Transferred Other Current BusinessCombinationConsiderationTransferredOtherCurrent	2359000	USD
CY2022Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	3003000	USD
CY2021Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	2639000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	14516000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	13924000	USD
CY2022Q1	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	6785000	USD
CY2022Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	USD
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	109000	USD
CY2022Q1	us-gaap	Accrued Insurance Noncurrent AccruedInsuranceNoncurrent	1728000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	205000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1168000	USD
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	14000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	4000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2442000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3717000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	42000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4734000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	46000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4089000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	38000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3370000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	1000	USD
CY2022Q1	toi	Lessee Operating Lease Liability To Be Paid Thereafter LesseeOperatingLeaseLiabilityToBePaidThereafter	2505000	USD
CY2022Q1	toi	Finance Lease Liability To Be Paid Thereafter FinanceLeaseLiabilityToBePaidThereafter	0	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	20857000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	131000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2171000	USD
CY2022Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	7000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	18686000	USD
CY2022Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	124000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4277000	USD
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	50000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14409000	USD
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	74000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	18686000	USD
CY2022Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	124000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M21D
CY2022Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M29D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0421
CY2022Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0439
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1145000	USD
CY2022Q1	toi	Repayments For Finance Lease RepaymentsForFinanceLease	17000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	19598000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	40000	USD
CY2022Q1	toi	Operating Lease Modification Liability Increase Decrease OperatingLeaseModificationLiabilityIncreaseDecrease	775000	USD
CY2022Q1	toi	Operating Lease Modification Liability Increase Decrease Net Of Lease Incentives OperatingLeaseModificationLiabilityIncreaseDecreaseNetOfLeaseIncentives	682000	USD
CY2022Q1	toi	Operating Lease Modification Increase Decrease In Rent Expenses OperatingLeaseModificationIncreaseDecreaseInRentExpenses	3000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	180000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	218000	USD
CY2022Q1	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-38000	USD
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0092
CY2021Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.2802
CY2022Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022Q1	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	0.0001
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	163510	shares
CY2022Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	100	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73276230	shares
CY2021Q4	toi	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	591
CY2022Q1	toi	Common Stock Votes Per Share CommonStockVotesPerShare	1	vote
CY2022Q1	toi	Preferred Stock Maximum Percent Of Common Stock Allowed PreferredStockMaximumPercentOfCommonStockAllowed	0.049
CY2021Q4	toi	Class Of Warrant Or Right Threshold Number Of Business Days Before Sending Notice Of Redemption To Warrant Holders ClassOfWarrantOrRightThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders	3	D
CY2021	us-gaap	Loss Contingency Accrual Payments LossContingencyAccrualPayments	350000	USD
CY2021	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	5	businessCombination
CY2021	toi	Number Of Asset Acquired NumberOfAssetAcquired	1	asset_acquisition
CY2021Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.00
CY2021Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	275000000	USD
CY2021Q4	toi	Reverse Recapitalization Net ReverseRecapitalizationNet	762052000	USD
CY2021Q4	toi	Reverse Recapitalization Equity Consideration Value ReverseRecapitalizationEquityConsiderationValue	595468000	USD
CY2021Q4	toi	Reverse Recapitalization Equity Consideration Shares ReverseRecapitalizationEquityConsiderationShares	51300000	shares
CY2021Q4	toi	Payments As A Result Of Recapitalization Transaction PaymentsAsAResultOfRecapitalizationTransaction	167510000	USD
CY2021Q4	toi	Reverse Recapitalization Expenses ReverseRecapitalizationExpenses	39914000	USD
CY2021Q4	toi	Accrued Reverse Recapitalization Costs AccruedReverseRecapitalizationCosts	6769000	USD
CY2021Q4	toi	Common Stock Votes Per Share CommonStockVotesPerShare	1	vote
CY2021Q4	toi	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	591
CY2021Q4	toi	Adjustments To Additional Paid In Capital Reverse Recapitalization AdjustmentsToAdditionalPaidInCapitalReverseRecapitalization	142557000	USD
CY2022Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	409000	USD
CY2021Q4	toi	Reverse Recapitalization Equity Consideration Share Price ReverseRecapitalizationEquityConsiderationSharePrice	10.00
CY2021Q4	toi	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	166584000	USD
CY2021Q4	toi	Proceeds From Reverse Recapitalization Transaction ProceedsFromReverseRecapitalizationTransaction	333946000	USD
CY2021Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	76000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	26479000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8907000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	26626000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17572000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	26479000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8234000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18245000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2011000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2639000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2639000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2639000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2617000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	5027000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17572000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	673000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	612000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	26626000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	26626000	USD
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	26626000	USD
CY2020Q4	us-gaap	Goodwill Gross GoodwillGross	14227000	USD
CY2022Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	12399000	USD
CY2022Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
CY2022Q1	us-gaap	Goodwill Goodwill	26626000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	19286000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-996000	USD
CY2022Q1	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	3519000	USD
CY2021Q1	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	0	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	15767000	USD
CY2022Q1	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	3405000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-996000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73252365	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62853419	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.22
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	19286000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-996000	USD
CY2021Q1	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	0	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	15881000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-996000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	76247966	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62853419	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18471000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1753000	USD
CY2022Q1	us-gaap	Assets Assets	206512000	USD
CY2021Q4	us-gaap	Assets Assets	203439000	USD
CY2022Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	156000	USD
CY2021Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	41000	USD

Files In Submission

Name	View Source	Status
0001628280-22-013677-index-headers.html	Edgar Link	pending
0001628280-22-013677-index.html	Edgar Link	pending
0001628280-22-013677.txt	Edgar Link	pending
0001628280-22-013677-xbrl.zip	Edgar Link	pending
ex101-executiveemploymenta.htm	Edgar Link	pending
ex311-certificationrule13a.htm	Edgar Link	pending
ex312-certificationrule13a.htm	Edgar Link	pending
ex321-ceocertificationsect.htm	Edgar Link	pending
ex322-cfocertificationsect.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
toi-20220331.htm	Edgar Link	pending
toi-20220331.xsd	Edgar Link	pending
toi-20220331_cal.xml	Edgar Link	unprocessable
toi-20220331_def.xml	Edgar Link	unprocessable
toi-20220331_htm.xml	Edgar Link	completed
toi-20220331_lab.xml	Edgar Link	unprocessable
toi-20220331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TOI
Oncology Institute, Inc. Stock $toi

2022 Q2 Form 10-Q Financial Statement

#000162828022013677 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOI Oncology Institute, Inc. Stock $toi

2022 Q2 Form 10-Q Financial Statement

#000162828022013677 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOI
Oncology Institute, Inc. Stock $toi